Colin Molloy

1.7k total citations · 1 hit paper
11 papers, 988 citations indexed

About

Colin Molloy is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Cell Biology. According to data from OpenAlex, Colin Molloy has authored 11 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Cellular and Molecular Neuroscience and 3 papers in Cell Biology. Recurrent topics in Colin Molloy's work include Prion Diseases and Protein Misfolding (5 papers), Neuroscience and Neuropharmacology Research (4 papers) and Receptor Mechanisms and Signaling (4 papers). Colin Molloy is often cited by papers focused on Prion Diseases and Protein Misfolding (5 papers), Neuroscience and Neuropharmacology Research (4 papers) and Receptor Mechanisms and Signaling (4 papers). Colin Molloy collaborates with scholars based in United Kingdom, United States and Australia. Colin Molloy's co-authors include Nicholas Verity, Giovanna R. Mallucci, Helois Radford, Julie A. Moreno, Mark Halliday, David A. Barrett, Catharine A. Ortori, Anne E. Willis, Jeffrey M. Axten and Peter M. Fischer and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Colin Molloy

11 papers receiving 973 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

2013 453 citations Julie A. Moreno, Mark Halliday et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Colin Molloy

Since Specialization

Citations

This map shows the geographic impact of Colin Molloy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colin Molloy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colin Molloy more than expected).

Fields of papers citing papers by Colin Molloy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colin Molloy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colin Molloy. The network helps show where Colin Molloy may publish in the future.

Co-authorship network of co-authors of Colin Molloy

This figure shows the co-authorship network connecting the top 25 collaborators of Colin Molloy. A scholar is included among the top collaborators of Colin Molloy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colin Molloy. Colin Molloy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Optical, contact-free assessment of brain tissue stiffness and neurodegeneration 2024 ·Biomedical Optics Express ·(unknown), (unknown), Gonzalo S. Tejeda, (unknown), Colin Molloy, (unknown), Matthew C. Walker, Massimo Vassalli, Andrew B. Tobin	2
2	M ₁ muscarinic receptor activation reduces the molecular pathology and slows the progression of prion-mediated neurodegenerative disease 2022 ·Science Signaling ·Louis Dwomoh, Mario Rossi, (unknown), Elham Khajehali, Colin Molloy, Pawel Herzyk, Shailesh N. Mistry, Andrew R. Bottrill, Patrick M. Sexton, Arthur Christopoulos, P. Jeffrey Conn, Craig W. Lindsley, Sophie J. Bradley, Andrew B. Tobin	14
3	Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease 2021 ·Proceedings of the National Academy of Sciences ·(unknown), Colin Molloy, Laura Jenkins, (unknown), (unknown), (unknown), Louis Dwomoh, Sara Marsango, Gonzalo S. Tejeda, Mario Rossi, Zeshan Ahmed, Graeme Milligan, Brian D. Hudson, Andrew B. Tobin, Sophie J. Bradley	16
4	Targeting the kinase insert loop of PERK selectively modulates PERK signaling without systemic toxicity in mice 2020 ·Science Signaling ·Daniel T. Hughes, Mark Halliday, Heather Smith, Nicholas Verity, Colin Molloy, Helois Radford, Adrian J. Butcher, Giovanna R. Mallucci	13
5	Restoring Agonist Function at a Chemogenetically Modified M₁Muscarinic Acetylcholine Receptor 2020 ·ACS Chemical Neuroscience ·Elham Khajehali, Sophie J. Bradley, Emma T. van der Westhuizen, Colin Molloy, Céline Valant, L. H. Finlayson, Craig W. Lindsley, Patrick M. Sexton, Andrew B. Tobin, Arthur Christopoulos	1
6	Chemogenetics defines receptor-mediated functions of short chain free fatty acids 2019 ·Nature Chemical Biology ·Daniele Bolognini, (unknown), Adrian J. Butcher, Brian D. Hudson, Eugenia Sergeev, Colin Molloy, (unknown), Sophie J. Bradley, Christian Le Gouill, Michel Bouvier, Andrew B. Tobin, Graeme Milligan	56
7	Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes 2018 ·Molecular Pharmacology ·Sophie J. Bradley, Colin Molloy, Christoffer Bundgaard, Adrian J. Mogg, Karen Thompson, Louis Dwomoh, Helen Sanger, Michael Crabtree, (unknown), Patrick M. Sexton, Christian C. Felder, Arthur Christopoulos, Lisa M. Broad, Andrew B. Tobin, Christopher J. Langmead	21
8	Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice 2017 ·Brain ·Mark Halliday, Helois Radford, (unknown), Colin Molloy, Julie A. Moreno, Nicholas Verity, Ewan M. Smith, Catharine A. Ortori, David A. Barrett, Martin Bushell, Giovanna R. Mallucci	213
9	RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration 2015 ·Nature ·Diego Peretti, Amandine Bastide, Helois Radford, Nicholas Verity, Colin Molloy, Maria Guerra Martin, Julie A. Moreno, Joern R. Steinert, Tim Smith, David Dinsdale, Anne E. Willis, Giovanna R. Mallucci	181
10	Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice breakdown → 2013 ·Science Translational Medicine ·Julie A. Moreno, Mark Halliday, Colin Molloy, Helois Radford, Nicholas Verity, Jeffrey M. Axten, Catharine A. Ortori, Anne E. Willis, Peter M. Fischer, David A. Barrett, Giovanna R. Mallucci	453
11	Stimulation of Platelet Production in Healthy Volunteers by a Novel Pegylated Peptide-Based Thrombopoietin (TPO) Receptor Agonist. 2005 ·Blood ·(unknown), Kathryn H. Brown, Robert A. Harris, D End, Colin Molloy, Edward J. Yurkow, Holly K. Koblish, Carol F. Franks, (unknown), (unknown)	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact